Multiple CRB projects selected for 2022 Facility of the Year Awards by ISPE
May 26, 2022
Three critical life sciences projects served by CRB and focused on speeding life-saving therapies and vaccines to patients have earned Facility of the Year Awards (FOYA) honors from the International Society for Pharmaceutical Engineering (ISPE).
The annual awards, announced in late April at the 2022 ISPE Europe Annual Conference in Madrid, Spain, recognize state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. Facilities receiving ISPE’s recognition included:
- Catalent Pharma Solutions, which received the 2022 FOYA for Social Impact for its Aseptic and Sterile Drug Product facility in Bloomington, Indiana. Delivered during the pandemic to meet global demand for commercial-scale COVID-19 vaccine production, CRB’s ONEsolution™ project delivery approach fueled a four-story renovation project that included numerous design and scheduling innovations – as well as critical safety and sustainability elements – to allow the project to progress even as “the constant threat of the COVID-19 virus hung over the entire project,” ISPE said.
- Takeda Pharmaceuticals, which received the 2022 FOYA for Supply Chain for its work to completely rethink the supply chain management program for Takeda’s first allogeneic mesenchymal stem cell therapy. As part of the project, CRB’s ONEsolution approach was utilized at the Thousand Oaks, California, facility to support the final product production including receiving frozen drug substances to packaging and labeling of finished filled product for shipment to clinics.
- Iovance Biotherapeutics, Inc., which received the 2022 FOYA Honorable Mention for its Iovance Cell Therapy Center (iCTC) in Philadelphia, Pennsylvania. CRB worked with Iovance to design and construct the first centralized, scalable, state-of-the-art manufacturing facility dedicated to producing tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. With approximately 136,000 square feet of space, the iCTC is among the largest cell therapy manufacturing facilities today.